14 Lone Pine, Irvine, Ca 92604
Our Story
2011
Recognizing that high costs and limited access restrict proper surgical care globally, the doctors begin to work on a reliable, cost-effective device built to improve ARM procedures globally.
2013
Driven by international demand, Drs. Frykman and Kimble plus colleagues found The Global Pediatric Surgical Technology and Education Project (GPSTEP) and began to develop a low-cost, sterilizable muscle stimulator device.
2014
2020
Together, AirLife and Dr. Frykman enhance the functionality and use of the stimulator device and redesign the probe to be a single-use stylus. Airlife conducts full technical testing, safety verification, and packaging.
2024
The FDA Cleared MYOTouch Muscle Stimulator is available for use in the United States through the Mainline Medical Website.
2026
While providing pediatric care in China, surgeon Dr. Philip Frykman and anesthesiologist Dr. Keith Kimble perform anorectal malformation (ARM) repairs on babies using improvised methods.
2012
The European Journal of Pediatric Surgery publishes an article (authored by Drs. Frykman, Kimble et al) hypothesizing that low-cost nerve stimulators are equally effective as high-cost muscle stimulators in ARM surgery. The findings trigger widespread interest from surgical teams across Asia, Latin America, and the Caribbean.
2013
2017
Drs. Frykman and Kimble partner with SunMed (now AirLife), combining clinical insight with engineering and quality management to design the next ARM muscle stimulator.
2021
The AirLife Quality Management team navigates the FDA medical device application process for the ARM device and secures 510K clearance for the MYOTouch Muscle Stimulator
2025
GPSTEP continues to serve surgical teams around the globe through its distribution of reliable, cost-effective muscle stimulators.
Backed by funding from Mending Kids, GPSTEP builds early prototypes. The team conducts procedures and training with the prototype in South Africa.
GPSTEP begins to search for a partner to help refine the device for clinical use in the US market.